喘息の急性増悪で入院した小児では、短時間作用型β2作動薬に抗コリン作動薬の噴霧を追加した場合、入院期間および治療に対する反応の他のマーカーに利益をもたらすエビデンスは認められなかった。
入院中の急性喘息の小児に対する吸入抗コリン薬および短時間作用型ベータ(2)作動薬と短時間作用型ベータ 2 作動薬単独の比較 https://t.co/TU9g2MQyQF
Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children… http://t.co/At0mgiDtGV
Anticolinérgicos + β2-agonistas: no beneficio en niños ingresados por exacerbación aguda de asma http://t.co/PvZWPm2Gx7
Anticolinérgicos añadidos a β2-agonistas no suponen beneficio en niños ingresados por exacerbación aguda de asma http://t.co/MmyXN6DOxB
Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children... http://t.co/WlnGOqK282
Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children... http://t.co/mf1cBSW1tt
Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children... http://t.co/cnr3z8Jkr2
reviews supports recommendations that practitioners refrain from using anticholinergics in kids hospitalised w/asthma http://t.co/gFhtF1nkUj
reviews supports recommendations that practitioners refrain from using anticholinergics in kids hospitalised w/asthma http://t.co/gFhtF1nkUj
reviews supports recommendations that practitioners refrain from using anticholinergics in kids hospitalised w/asthma http://t.co/gFhtF1nkUj
...and no serious or non-serious adverse events were reported in any included trials. http://t.co/zlwxJ57Ibk
No evidence of effect on duration of hospital stay MD -0.28 h 95%CI -5.07 to 4.52, n=327, moderate qual evidence http://t.co/clX0MmdjZ0
Ipratropium bromide 250 μg, was given every 1-8 hours over a period from 4 hours to the length of the hospital stay http://t.co/PVCS7496wS
review included 7 RCTs, 4 of which reported usable data on 472 children with asthma one admitted to paediatric wards http://t.co/ZnSzvyF0j5
New #Cochrane review: Inhaled anticholinergics and SABA versus SABA alone for children with acute asthma in hospital http://t.co/G9jnPIThBD